Related Experiment Video

Updated: May 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K

Antidiabetic potential of the heme oxygenase-1 inducer curcumin analogues

Yong Son1, Ju Hwan Lee, Yong-Kwan Cheong

  • 1Department of Anesthesiology and Pain Medicine, Wonkwang University School of Medicine, 460 Iksandae-ro, Iksan 570-749, Republic of Korea.

Biomed Research International
|November 6, 2013
PubMed

Insights

Heme oxygenase-1 (HO-1) offers cellular protection against diabetes by reducing oxidative, inflammatory, and ER stress. Inducing HO-1 expression shows therapeutic potential for treating diabetic diseases.

Area of Science:

  • Biomedical Research
  • Molecular Biology
  • Pathophysiology

Background:

  • Diabetes mellitus is linked to cardiovascular disease risk due to chronic inflammation, oxidative stress, and endoplasmic reticulum (ER) stress.
  • The interplay of these stresses is crucial in the development of diabetic complications.
  • Heme oxygenase-1 (HO-1) is a key cellular protective molecule with antioxidant, anti-inflammatory, and antiapoptotic properties.

Purpose of the Study:

  • To review the protective mechanisms of HO-1 in diabetes.
  • To explore therapeutic strategies targeting HO-1 expression for diabetic diseases.
  • To evaluate the potential of curcumin analogues in inducing HO-1.

Main Methods:

  • Literature review of studies on HO-1 and diabetes.
  • Analysis of molecular pathways involving HO-1, oxidative stress, inflammation, and ER stress.
  • Examination of evidence for therapeutic interventions targeting HO-1.

Main Results:

  • HO-1 effectively mitigates oxidative, inflammatory, and ER stress implicated in diabetes pathogenesis.
  • Modulating HO-1 activity presents a promising therapeutic avenue for managing diabetic conditions.
  • Curcumin analogues demonstrate potential inducers of HO-1, suggesting a role in treatment.

Conclusions:

  • HO-1 plays a significant protective role in combating the multifaceted stresses associated with diabetes.
  • Targeting HO-1 expression offers a viable strategy for developing novel treatments for diabetic diseases.
  • Further research into HO-1 induction, particularly via agents like curcumin analogues, is warranted for therapeutic application.

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

14.5K
High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

10.8K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
958
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K